TL;DR
Get sports gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Kivo Health raised $10 million in a Series A round led by Allumia Ventures, bringing its total financing to $16 million. The Seattle startup plans to expand its virtual home-care program nationwide and says it aims to serve tens of thousands of patients within two years.
Kivo Health, a Seattle-based provider of virtual home care for chronic lung disease, has raised $10 million in Series A financing to fund a planned nationwide expansion. The round brings the company’s total financing to $16 million and comes as Kivo says it intends to extend its care model beyond COPD to other costly chronic illnesses.
Allumia Ventures led the funding round. Other participants were Corewell Health Ventures, Y Combinator, Heuristic Capital and MassMutual Ventures, according to Home Health Care News. The report did not provide details on the company’s valuation or the terms of the investment.
Kivo’s service is designed for people managing chronic obstructive pulmonary disease (COPD) at home. After enrollment, patients receive a care kit that includes a tablet, an oxygen monitor and exercise bands. They meet virtually with a respiratory therapist for an assessment and an individualized plan, then take part in small-group sessions twice a week for nine weeks, according to the company’s website.
Those sessions cover breathing techniques, targeted exercises and resources for managing COPD. CEO and co-founder Victor Sadauskas told Home Health Care News by email that Kivo has delivered tens of thousands of sessions and provided care to thousands of patients. He said the company plans to expand nationwide and reach tens of thousands of patients in the next two years.
Funding Supports Broader Patient Reach
The financing gives Kivo capital to pursue a wider geographic footprint for a service that aims to support patients between clinical visits. For people with COPD, the company’s model combines remote contact with a respiratory therapist, guided exercise and home monitoring rather than relying solely on periodic in-person appointments. Whether that approach improves outcomes at a larger scale will depend on patient uptake and measured results.
Kivo says its program can reduce avoidable hospitalizations, emergency department visits and nursing home days. The company also claims it lowers total health spending by $8,245 per member per year. That figure is a company-reported savings claim; the supplied report does not describe the study design, comparison group or time period behind the calculation.
The stated expansion plan could bring the program to more patients and health plans, while Kivo’s intention to address other high-cost chronic illnesses would widen its scope. The funding announcement alone does not establish that the service has produced the claimed savings across all populations or that the company has already secured nationwide availability.
Products Worth Considering
Garmin Index BPM Smart Blood Pressure Monitor
GoPro Hero12 Black Waterproof Action Camera with 5.3K60 Video and 27MP Photos
GoPro Fluid Pro AI 3-Axis Gimbal Stabilizer
As an affiliate, we earn on qualifying purchases.
How Kivo’s COPD Program Works
Kivo’s current care model centers on home-based COPD management. A respiratory therapist assesses a patient’s symptoms and develops an individual plan, followed by a nine-week course of twice-weekly virtual group sessions. The home kit supplies equipment for participation and monitoring, while the therapist provides instruction and support.
The company says its program is covered by Medicare, Medicaid and several commercial insurers, including UnitedHealthcare, Humana, Blue Cross, Aetna and Priority Health. Coverage can vary by plan and patient eligibility; the source report does not detail the requirements or availability in each market.
The Series A follows earlier financing that brings Kivo’s cumulative funding to $16 million. The announcement describes nationwide expansion and possible development for additional chronic conditions as plans, not completed rollouts or already-launched services.
“We have delivered tens of thousands of sessions, providing thousands of patients access to care that improves symptoms and saves health plans money by reducing unnecessary hospitalizations, ER visits and nursing home days.”
— Victor Sadauskas, Kivo Health co-founder and CEO, in an email to Home Health Care News
Expansion and Savings Still Unverified
The report does not specify when Kivo expects to enter each new market, how the funding will be allocated or how many patients are currently enrolled. It also does not say whether “tens of thousands” refers to patients served over the two-year period or an active patient count at a particular date.
Kivo’s reported $8,245 annual savings per member is not accompanied in the source material by a methodology, baseline or independent evaluation. The company’s statements that care improves symptoms and reduces hospital use are attributed claims; the report does not provide patient-outcome data for independent review.
It is also unclear which additional chronic illnesses Kivo may target, when those programs could launch, and whether the existing insurance coverage will extend to any new services. The company’s national expansion goal should not be taken to mean the program is currently available in every state.
Kivo’s Two-Year Expansion Plan
Kivo says it plans to use the new financing to expand nationwide and reach tens of thousands of patients over the next two years. The company has also said it intends to adapt its care model for other high-cost chronic illnesses, but has not identified those conditions or given a launch schedule in the supplied report.
Further details to watch for include where the service becomes available, how Kivo measures patient outcomes and healthcare spending, and whether it publishes evidence supporting its savings claims. Until those details are released, the funding and expansion goals are confirmed, while the reach and results of the planned rollout remain to be seen.
Key Questions
How much did Kivo Health raise?
Kivo raised $10 million in Series A financing. The round brings its total financing to $16 million, according to Home Health Care News.
Who led the funding round?
Allumia Ventures led the round. Corewell Health Ventures, Y Combinator, Heuristic Capital and MassMutual Ventures also participated.
What care does Kivo currently provide?
Kivo’s reported program focuses on COPD management at home, with virtual respiratory-therapist assessments and twice-weekly small-group sessions over nine weeks. Patients receive a tablet, oxygen monitor and exercise bands as part of a care kit.
Is Kivo available nationwide now?
The company plans to expand nationwide, but the funding report does not confirm that its service is currently available in every state. Kivo says its program is covered by Medicare, Medicaid and several commercial health plans, subject to plan and eligibility details.
Has Kivo independently verified its reported savings?
The company claims savings of $8,245 per member per year, but the supplied report does not include the calculation method or independent validation. The figure should be treated as a company claim, not an independently established result.
Source: homehealthcarenews.com
